Jian Teng, Ph.D., Massachusetts General Hospital
one-year 2018-2019 final summary
I want to take this opportunity to sincerely thank CBTF for your funding to my proposal of using a subset of quinoline methanol anti-malaria agents in killing pediatric brain cancer cells. This funding helps us get one step closer to our goal. With the funding from CBTF, I tested several mefloquine analogs in cultured cells and in mouse models, and generated enough preliminary results to initiate two important collaborations, each with proposal to apply funding from NIH or DOD.
1. With Broad Institute at MIT, which can provide all the cutting-edge technologies to support this project.
2. With the Walter Reed Army Institute of Research (WRAIR), which is the original developer of mefloquine and they have more than 300,000 analogs available and agreed to provide any promising compounds for us to test in treating pediatric brain cancers.
